Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT02824029
Phase
PHASE2
Status
Completed

Conditions

  • Classical Hodgkin Lymphoma
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibrutinib — DRUG
    Given PO
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Pharmacological Study — OTHER
    Correlative studies

Study Details

This phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, by altering the environment around the tumor or by affecting the immune system.

Key Dates

Start date
Jun 30, 2016
Status verified
Jan 2025
Primary completion
May 12, 2023
Completion
Jan 8, 2025

Study Design

Enrollment
28 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ibrutinib)
    Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: From date of study entry to date of progression or death up to 24 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of Michigan Health SystemAnn ArborMichigan48109-
Wayne State University/Karmanos Cancer InstituteDetroitMichigan48201-
University of TennesseeKnoxvilleTennessee37920-
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Health System· Ann Arbor, MIWayne State University/Karmanos Cancer Institute· Detroit, MIUniversity of Tennessee· Knoxville, TNM D Anderson Cancer Center· Houston, TX

Related Studies